Group items tagged

Not only do companies have the potential to achieve what Novavax was able to under the right circumstances, but the industry is also full of big mergers and acquisitions. Early-stage companies develop clinical trial pipelines. Larger companies may then target these smaller firms as buyout candidates. For instance, Merck (NYSE: MRK) bought cancer drug research company VelosBio Inc. from Pappas Capital and other investors for $2.75 billion. Gilead Sciences (NASDAQ: GILD) picked up Immunomedics for $21 billion to gain access to a breast cancer treatment, Trodelvy. The list goes on. In this article, we'll look at a few current and former biotech penny stocks that have continued demonstrating strength in the stock market in 2021.

Some of the latest published analysis of Merck indicates a yield of as much as 4.6 percent after three quarters of strong earnings. At its current low-price Merck is gaining appeal.